Otsuka has a proud history of developing and delivering medicines in the following therapeutic areas: central nervous system, nephrology and haematology. We have a number of approved products in Australia and many new treatments are being developed in areas such as haematology/oncology.

To view the Product Information (PI) and Consumer Medical Information (CMI) for each of our products currently available in Australia, please click on the links below:

Approved products in Australia

For healthcare professionals
ABILIFY MAINTENA® (aripiprazole (as monohydrate))*
PI
Abilify® (aripiprazole)
PI
Busulfex® (busulfan)
PI
Jinarc® (tolvaptan)
PI
Samsca® (tolvaptan)
PI
REXULTI® (brexpiprazole)*
PI
For consumers
ABILIFY MAINTENA® ((aripiprazole (as monohydrate)) )*
CMI
Abilify® (aripiprazole)
CMI
Busulfex® (busulfan)
CMI
Jinarc® (tolvaptan)
CMI
Samsca® (tolvaptan)
CMI
REXULTI® (brexpiprazole)*
CMI

*Abilify Maintena® and Rexulti® are sponsored by Lundbeck Australia.

*Abilify Maintena® and Rexulti® are co-commercialised by Lundbeck Australia and Otsuka Australia Pharmaceutical Pty Limited.

Lundbeck Australia Pty Limited
Ground Floor
1 Innovation Road
North Ryde NSW 2113
Ph: +61 2 8669 1000

Otsuka Australia Pharmaceutical Pty Limited
Suite 2.03, Level 2
9 Help Street
Chatswood NSW 2067

For further information about any of these products, please contact us.

Products: ABILIFY® (maintena), Abilify® (aripiprazole), Busulfex® (busulfan)Jinarc® (tolvaptan), Pletal® (cilostazol), Samsca® (tolvaptan), REXULTI® (brexpiprazole)